Dr. Benoit Bouche Appointed Chairman of NEOMED-LABS Board of Directors
Laval, January 31, 2017
NEOMED-LABS, a Contract Research Organization (CRO) providing customized and high-throughput immune-monitoring for clinical vaccine development, is pleased to announce the appointment of Dr. Benoit Bouche, as Chairman of the Board of Directors.
Dr. Bouche is currently Managing Partner of Trans-Hit Bio, a worldwide biospecimen access CRO located at the NEOMED Institute Laval. Prior to joining Trans-Hit Bio, he founded and directed several companies in the Life Sciences sector including: Astel Laboratories (acquired by Zimmer/BMS); FDM Pharma, a clinical stage CRO of which central laboratory activities were acquired by MDS Pharma (now LabCorp); and Galien Development, a regional network of pharmacies. He has worked as an investment banker and advisor for multiple healthcare companies on innovation and growth-related issues. Over his career, he has been instrumental in the initiation and execution of more than 40 M&A transactions and financings. Dr. Bouche holds a Pharmacy and a PhD degree in Biotechnology from the University of Lille, France, and an Advanced Management Program from the Harvard Business School.
“We are extremely excited to have been able to attract someone of Dr. Bouche’s calibre to join and chair NEOMED-LABS Board of Directors as we enter an important period of growth and expansion. He has the hands-on experience and established global network that will be invaluable as NEOMED-LABS continues to expand the scope and scale of its product offerings” declared Donald Olds, President and CEO of the NEOMED Institute.
“I am truly honoured to be given the opportunity to contribute to the growth and success of NEOMEDLABS. From its official launch less that one year ago, the company has clearly established its ability to effectively and efficiently deliver consistent, high-quality data to support worldwide clinical vaccine development programs”, said Dr. Benoit Bouche.
“It is with great enthusiasm that I welcome Benoit as Chairman of our Board of Directors. With his extensive entrepreneurial background, his European presence and international network, and his deep experience in growing healthcare businesses, Benoit will bring great value to the continued evolution and strategic direction of NEOMED-LABS”, said Dr. Luc Vachon, President and CEO of NEOMED-LABS.
NEOMED-LABS is governed by an independent Board of Directors playing an active role at both corporate and strategic levels, providing guidance and support to NEOMED-LABS management team. The Board of Directors also include Dr. Max Fehlmann as independent Director (former President and CEO), Dr. Luc Vachon (former Chairman of the Board and newly appointed interim President and CEO of NEOMEDLABS), Dr. Michael Berendt, Chairman of the Nominating and Corporate Governance Committee of the NEOMED Institute and Mr. Donald Olds, former Chairman of the Board of the NEOMED Institute and newly appointed President and CEO of the NEOMED Institute.
NEOMED-LABS is a Contract Research Organization (CRO) offering high-quality clinical immunology laboratory services. NEOMED-LABS serves pharmaceutical corporations, biotechnology companies, and healthcare / non-profit organizations with its extensive expertise in delivering quality readouts for the clinical development of vaccines and immunotherapies. Currently, NEOMED-LABS supports clinical vaccine development programs of multinational pharma companies. The staff consists of over 60 experienced, dedicated scientists and technical experts, and the projects are supported by an extensive network of key opinion leaders as scientific advisors and consultants. NEOMED-LABS conducts GCLP-compliant immunemonitoring activities to support Phase I to Phase IV vaccine clinical trials. Located at the NEOMED Institute Laval (Quebec, Canada), an important scientific hub in North America, the company benefits from cuttingedge technology platforms and state-of-the-art laboratories with BSL 2 and BSL 3 facilities.
For more information, please visit: www.neomedlabs.com
ABOUT NEOMED Institute
The NEOMED Institute is a not-for-profit organization whose mission is to create a bridge between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with funding and a favorable ecosystem, to transform innovations into solid therapeutic solutions. NEOMED drives drug discovery activities up to the stage of human proof of concept. The NEOMED Institute has two fully integrated research and development campuses: one in Ville Saint-Laurent, specializing in small molecule therapeutics, and the other facility, specializing in the development of biologics and vaccines, in Laval. Both facilities function as open-access drug discovery hubs housing independent commercial businesses (30 independent companies employing almost 300 people) and providing a dynamic environment that stimulates collaboration, innovation, and creativity. NEOMED-LABS is the NEOMED Institute’s first independent commercial subsidiary.
The NEOMED Institute is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada.
For more information, please visit: www.neomed.ca